KRAS G12C vs G12D: Similar Gene, Different Alterations
KRAS G12C and G12D both alter codon 12, but they substitute different amino acids and have different chemical and structural properties. Grouping them only as 'KRAS mutations' can obscure the distinction that a report, study or clinical discussion may require.
Quick Answer
KRAS G12C and G12D both alter codon 12, but they substitute different amino acids and have different chemical and structural properties. Grouping them only as 'KRAS mutations' can obscure the distinction that a report, study or clinical discussion may require.
The Shared Feature
Both variants change glycine 12 in the KRAS G-domain and can weaken normal GTPase control. Both may therefore support signalling through RAS effector networks.
This shared mechanism does not make them identical. The replacement amino acid changes local chemistry and can influence conformation, nucleotide cycling and interactions.
Why the Distinction Matters
G12C contains cysteine; G12D contains aspartate. These are separate molecular targets and their biology should not be inferred from each other without supporting evidence in the relevant tumour type.
Comparative laboratory and model studies can generate hypotheses, but model findings should not be treated as an individual prognosis or treatment recommendation.
Key Takeaways
- ·G12C and G12D share a codon but are distinct alterations.
- ·The amino-acid change affects biochemical context.
- ·Use variant-specific evidence and the exact tumour setting when interpreting either result.
Put these genes in pathway context
Frequently asked questions
What is the key idea in KRAS G12C vs G12D: Similar Gene, Different Alterations?
KRAS G12C and G12D both alter codon 12, but they substitute different amino acids and have different chemical and structural properties. Grouping them only as 'KRAS mutations' can obscure the distinction that a report, study or clinical discussion may require.
What should be kept with the result or mechanism?
G12C and G12D share a codon but are distinct alterations. The amino-acid change affects biochemical context. Use variant-specific evidence and the exact tumour setting when interpreting either result.
References
Continue Reading
KRAS G12D Mutation: Biology, Testing and Context
2 min read
KRAS G12V Mutation: How to Interpret the Finding
2 min read
KRAS G12C in Colorectal Cancer: Biomarker Context
4 min read
KRAS Mutations: Constitutive MAPK Signalling and Targeted Therapy
6 min read
KRAS vs NRAS vs HRAS: Three RAS Genes, Different Cancers
3 min read
Sotorasib vs Adagrasib: Two KRAS G12C Inhibitors Compared
3 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.
KRAS has 500+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.